Testing the Effect of Sulforaphane, a Compound Naturally Found in Cruciferous Vegetables, on Preventing Melanoma in Patients With a Prior History of Melanoma

Not Applicable

Not yet recruiting

• Conditions: Melanoma
• Interventions: Drug: Sulforaphane (broccoli sprout extract); Drug: Placebo; Device: Derma-AI

• Registration Number: NCT07040280
• Lead Sponsor: Eastern Cooperative Oncology Group

Brief Summary

The goal of this clinical trial is to compare the safety and effects of sulforaphane with the safety and effects of placebo on people's risk of developing melanoma. The main question it aims to answer is:

Will giving sulforaphane (a broccoli sprout extract) have a meaningful effect on how your atypical moles change over time? If there is an effect, will this lower your risk of developing melanoma?

Participants will:

Take sulforaphane or a placebo for 12 months Visit the clinic once every 3 months for checkups and tests You will keep a calendar which will help you keep track of when you take your tablets

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-06
• Study First Submitted: 2025-06-17
• Study First Submitted QC: 2025-06-24
• Last Update Submitted: 2025-06-24
• Study First Posted: 2025-06-27
• Last Update Posted: 2025-06-27
• Study Start: 2025-10-31
• Primary Completion: 2029-02-01
• Study Completion: 2029-08-01

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

• Patient must have ≥ 3 clinically atypical nevi, assessed within 30 days prior to randomization, that are consistent with the International Agency for Research on Cancer (IARC) definition as follows.27
• Must have a diameter of ≥ 5mm in one dimension
• Must include a macular component in at least one area
• Must have at least two of the following features: ill-defined borders, color variegation, uneven contour, and erythema
• Patient must have a prior diagnosis of early-stage melanoma, defined as either melanoma in situ, localized resected stage I-II node negative melanoma, or resected node positive stage III melanoma who in the assessment of their physician have a low risk of relapse of their prior melanoma within one year of randomization.
• Patient must not be currently on targeted or checkpoint immunotherapy or treated within 365 days prior to randomization.
• Patient must be ≥ 18 years of age.
• Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible.
• Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of randomization are eligible for this trial.
• For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.
• Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
• Patients with a prior or concurrent malignancy (other than the melanoma for which they are on this study), whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen, are eligible for this trial.

Exclusion Criteria

• Patient must not be pregnant.
• Patient must not have a known allergy to cruciferous vegetables.
• Patients must not use any other sulforaphane-containing dietary supplement during the study period.
• Patient must not be on any current systemic treatment for melanoma.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
A	Sulforaphane (broccoli sprout extract)	Three tablets of Avmacol® Extra Strength \[Nutramax\] by mouth, once daily, for 12 months
A	Derma-AI	Three tablets of Avmacol® Extra Strength \[Nutramax\] by mouth, once daily, for 12 months
B	Placebo	Placebo - Three tablets by mouth, once daily, for 12 months
B	Derma-AI	Placebo - Three tablets by mouth, once daily, for 12 months

Primary Outcome Measures

Name	Time	Method
Changes in the total area of nevi after 12 months of treatment from the baseline between sulforaphane and placebo arms	12 months of treatment	The change in the total area of atypical and common pigmented nevocellular nevi measured at baseline and after 12 months of treatment, will be assessed in each patient who completed the full 12 months of treatment (with compliance assessed by dosing logs). The difference in the change of total area of nevi between the two arms will be compared using the Wilcoxon rank sum test.

Secondary Outcome Measures

Name	Time	Method
Change in number of atypical nevi at baseline and after the last treatment be assessed via automated image analysis	After 12 months of treatment	The number of changed atypical nevi at baseline and after the last treatment (12 months) will be assessed via automated image analysis. The difference in baseline and post-treatment measures will be compared between the two arms using the Wilcoxon rank-sum test.
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]	Over 12 months	Toxicity rate for individual AEs, categorized AEs and worst degree AEs will be compared between the two arms using the Fisher's exact test

Trial Locations

Locations (1)

UPMC Hillman Cancer Center; 🇺🇸 Pittsburgh, Pennsylvania, United States